Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study
African Health Sciences · 2024
DOI: 10.4314/ahs.v24i2.8 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Health Sciences, 2024. Verfasst von Lisa Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal. Hauptthemen laut MEDLINE: Amikacin, Diarylquinolines, Kanamycin, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Multidrug-resistant tuberculosis (MDR-TB) is a prevalent health burden, both in South Africa and globally. The treatment of MDR-TB is both complex and difficult as multiple drugs have to be used concurrently in order to achieve good treatment outcomes for patients. However, there is a lack in the evidence regarding the incidences of specific adverse effects of these drugs.
Objective
The main aim/objective of this study was to investigate and compare reported specific adverse drug reactions (ADRs) associated with kanamycin, capreomycin, amikacin and bedaquiline in MDR-TB patients.
Methods
Secondary data collected over a period of 12 months were sourced from a public access data base, VigiAccessTM, and analysed.
Results
There was a steep increase in adverse drug reactions reported for kanamycin with the main adverse reactions being hypoacusis, deafness and tinnitus cases, along with vomiting, nausea and diarrhoea. With capreomycin, there were increases in asthenia and hypoacusis although the latter showed a plateau after some point. Rash and pruritus increased along with cases of death with amikacin and there were reports of prolonged QT interval in the electrocardiogram of patients on bedaquiline in addition to nausea, vomiting and diarrhoea.
Conclusion
There are many specific adverse effects associated with kanamycin, capreomycin, amikacin and bedaquiline. The number of cases of the specific adverse effects also increased with time. Therefore, VigiAccessTM provides a good platform for reporting and awareness of specific adverse effects associated with MDR-TB therapy. This is a vital stepping stone for further research. Keywords: Kanamycin; Amikacin; Capreomycin; Bedaquiline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Health Science, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal.
- Division of Pharmacology (Therapeutics), Health Sciences, University of KwaZulu-Natal.
Zitieren
APA
Singh, L., Bangalee, V., Ramasir, S., & Mathibe, L. J. (2024). Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study. African Health Sciences. https://doi.org/10.4314/ahs.v24i2.8
Vancouver
Singh L, Bangalee V, Ramasir S, Mathibe LJ. Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study. African Health Sciences. 2024. doi:10.4314/ahs.v24i2.8
BibTeX
@article{Singh2024,
author = {Singh, Lisa and Bangalee, Varsha and Ramasir, Serisha and Mathibe, Lehlohonolo John},
title = {Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study},
journal = {African Health Sciences},
year = {2024},
doi = {10.4314/ahs.v24i2.8}
}
EUVIMED